An observational study in Pelvic Organ Prolapse and Genital Prolapse, sponsored by A.M.I. Agency for Medical Innovations GmbH. Active, not recruiting at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by A.M.I. Agency for Medical Innovations GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pelvic Organ Prolapse with a site in Germany — 4 open to participants now, 6 under way, none of them phase 3. Pelvic Organ Prolapse · Germany.
Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2025, is one of 14 observational ones, and was the 16th registered.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
Browse Pelvic Organ Prolapse studies →4 of the 19 studies in Pelvic Organ Prolapse with a site in Germany are open now. Recruiting first, the newest first:
A.M.I. Agency for Medical Innovations GmbH · Sites in Germany, Austria
Ages 18–80 · Women only
A.M.I. Agency for Medical Innovations GmbH · Sites in Germany, Austria
Ages 18+ · Women only
Promedon · Sites in Germany
Ages 18+ · Women only
Ethicon, Inc. · Sites in Germany, United States, Austria and 4 more countries
Ages 21+ · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 100 is below the median of 134 across 171 observational studies indexed under Pelvic Organ Prolapse.
Median enrollment 85 across the 5 interventional studies, 113 across the 14 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
A.M.I. Agency for Medical Innovations GmbH is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
A.M.I. Agency for Medical Innovations GmbH has 4 studies filed under Pelvic Organ Prolapse — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the clinical investigation is to generate clinical data to substantiate the safety and performance of the i-Stitch device for bilateral sacrospinous ligament fixation (SSLF) in pelvic organ prolapse (POP) repair.
The i-Stitch instrument is a reusable instrument for attaching sutures to tissue with or without surgical mesh implants in urogynaecology. It is used together with the i-Stitch loading units. The use of i-Stitch for the fixation of surgical urogynaecological mesh implants (e.g. BSC Mesh, InGYNious) has already been proven in several studies.
The aim of the present retrospective study is to generate clinical data to show the safety and performance of the i-Stitch instrument in bilateral sacrospinous ligament fixation (SSLF) without the use of a surgical mesh.
Patients with symptomatic pelvic organ prolapse indicated for a surgical intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilateral sacrospinous ligament fixation with i-Stitch device
Change in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)
German Pelvic Floor Questionnaire ("Deutscher Beckenboden-Fragebogen"): Validated patient-reported outcome measure assessing pelvic floor symptoms and their impact on quality of life. The questionnaire evaluates the domains of bladder function, bowel function, pelvic organ prolapse, and sexual function. Scores are calculated according to the validated scoring system. Scoring (domain scores from 0 to 10): higher scores indicate greater symptom burden and worse pelvic floor dysfunction.
Time frame: 12 months
Change in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)
German Pelvic Floor Questionnaire ("Deutscher Beckenboden-Fragebogen"): Validated patient-reported outcome measure assessing pelvic floor symptoms and their impact on quality of life. The questionnaire evaluates the domains of bladder function, bowel function, pelvic organ prolapse, and sexual function. Scores are calculated according to the validated scoring system. Scoring (domain scores from 0 to 10): higher scores indicate greater symptom burden and worse pelvic floor dysfunction.
Time frame: 3 months
Change in Urinary Incontinence Severity and Quality of Life (ICIQ-UI SF)
The ICIQ-UI SF is a validated patient-reported outcome measure that assesses the frequency, severity, and impact of urinary incontinence on daily life. Scoring: The total score ranges from 0 to 21, with higher scores indicating more severe urinary incontinence symptoms and greater impact on quality of life (worse outcome).
Time frame: 12 months
Percentage of Postoperative Complications
Complications in women undergoing bilateral SSLF using the i-Stitch
Time frame: 12 months
Anatomical outcome (POP-Q)
Anatomical outcome assessed using the Pelvic Organ Prolapse Quantification (POP-Q) system. Objective anatomical failure is defined as recurrent pelvic organ prolapse in any vaginal compartment (anterior, apical, or posterior) identified at the 12-month follow-up examination.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Jul 2026, 18 months.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
A.M.I. Agency for Medical Innovations GmbH